Unitaid transparency policy
Policy on ethics and conflict of interest for Unitaid
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Biomarkers for acute febrile illness at the point-of-care in low-resource settings. Meeting report
Accelerating access to innovative point-of-care HIV diagnostics: Lessons learned from UNICEF
Innovative delivery systems for paediatric medicines technology landscape
Disease Narrative for hepatitis C
Disease narrative for tuberculosis
Disease Narrative for malaria
Disease Narrative for HIV
Hepatitis C diagnostics technology landscape – May 2019
Unitaid and the Government of Spain
About Unitaid (Saving lives faster)
Unitaid and the UK Government
Unitaid audited financial report for the year ended 31 December 2023
Partnership report: Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria
Unitaid audited financial report for the year ended 31 December 2022
Landscape for HIV rapid diagnostic tests for HIV self-testing – 1st edition – Dec 2015
Strategic narrative: Hepatitis C in the context of co-infection with HIV
Hepatitis C medicines technology and market landscape – update
Tuberculosis diagnostics technology and market landscape – 4th edition
Tuberculosis diagnostics market in select high-burden countries current market and future opportunities for novel diagnostics
HIV/AIDS diagnostics technology landscape – 5th edition
Key Performance Indicators 2015
Patent landscape: velpatasvir
